Coronavirus disease 2019 (COVID-19) was declared a pandemic at the beginning of 2020, causing millions of deaths worldwide. Millions of vaccine doses have been administered worldwide; however, outbreaks continue. Probiotics are known to restore a stable gut microbiota by regulating innate and adaptive immunity within the gut, demonstrating the possibility that they may be used to combat COVID-19 because of several pieces of evidence suggesting that COVID-19 has an adverse impact on gut microbiota dysbiosis. Thus, probiotics and their metabolites with known antiviral properties may be used as an adjunctive treatment to combat COVID-19. Several clinical trials have revealed the efficacy of probiotics and their metabolites in treating patients with SARS-CoV-2. However, its molecular mechanism has not been unraveled. The availability of abundant data resources and computational methods has significantly changed research finding molecular insights between probiotics and COVID-19. This review highlights computational approaches involving microbiome-based approaches and ensemble-driven docking approaches, as well as a case study proving the effects of probiotic metabolites on SARS-CoV-2.
【저자키워드】 COVID-19, SARS-CoV-2, Probiotics, gut-lung axis, molecular docking, Microbiome, computational approach, 【초록키워드】 Treatment, Coronavirus disease 2019, Efficacy, clinical trial, pandemic, adaptive, Immunity, docking, molecular mechanism, vaccine dose, outbreak, Research, death, gut microbiota, molecular, resource, metabolite, Evidence, antiviral property, Gut, approaches, computational method, adverse impact, Administered, Effect, highlight, approach, significantly, changed, computational approach, patients with SARS-CoV-2, 【제목키워드】 role,